Years of life lost as a measure of cancer burden on a national level

por Brustugun, O T, Møller, B, Helland, Å
Publicado 2014

TP53 gene mutations and protein accumulation in primary vaginal carcinomas.

por Skomedal, H., Kristensen, G., Helland, A., Nesland, J. M., Kooi, S., Børresen, A. L., Holm, R.
Publicado 1995

Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.

por Helland, A., Karlsen, F., Due, E. U., Holm, R., Kristensen, G., Børresen-Dale, A. l.
Publicado 1998

TP53 mutations among molecular subtypes of HER2-positive tumors

por Helland, Å, Nicolau, M, Ji, Y, Langerød, A, Sommervoll, DE, Bergamaschi, A, Pollack, JR, Børresen-Dale, A-L, Jeffrey, SS
Publicado 2005

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival

por Wang, Y, Helland, Å, Holm, R, Skomedal, H, Abeler, V M, Danielsen, H E, Tropé, C G, Børresen-Dale, A-L, Kristensen, G B
Publicado 2004

Clinical significance of disseminated tumour cells in non-small cell lung cancer

por Rud, A K, Borgen, E, Mælandsmo, G M, Flatmark, K, Le, H, Josefsen, D, Solvoll, I, Schirmer, C B, Helland, Å, Jørgensen, L, Brustugun, O T, Fodstad, Ø, Boye, K
Publicado 2013

High number of kinome‐mutations in non‐small cell lung cancer is associated with reduced immune response and poor relapse‐free survival

por Helland, Å., Brustugun, O. T., Nakken, S., Halvorsen, A. R., Dønnem, T., Bremnes, R., Busund, L. T., Sun, J., Lorenz, S., Solberg, S. K., Jørgensen, L. H., Vodak, D., Myklebost, O., Hovig, E., Meza‐Zepeda, L. A.
Publicado 2017

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-c...

por Wolf, J., Helland, Å., Oh, I.-J., Migliorino, M.R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., Griesinger, F., Chlistalla, M., Cardona, A., Ruf, T., Trunzer, K., Smoljanovic, V., Novello, S.
Publicado 2022

Associations between patient-reported late effects and systemic cytokines in long-term survivors of head and neck cancer treated with radiotherapy

por Huynh, T. T. M., Aass, H. C. D., Falk, R. S., Astrup, G. L., Helland, Å., Bjøro, T., Bjordal, K., Dale, E., Hellebust, T. P., Herlofson, B. B., Malinen, E., Kiserud, C. E., Osnes, T., Amdal, C. D.
Publicado 2022

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

por Novello, S, Mazières, J, Oh, I -J, de Castro, J, Migliorino, M R, Helland, Å, Dziadziuszko, R, Griesinger, F, Kotb, A, Zeaiter, A, Cardona, A, Balas, B, Johannsdottir, H K, Das-Gupta, A, Wolf, J
Publicado 2018